CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 538 enrolled
Drug / intervention
Subetta +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03725033
NCT03725033Phase 3Completed
CompareCT.gov

Multicentre Double-blind Placebo-controlled Parallel Group Randomized Clinical Trial of Efficacy and Safety of Subetta in the Treatment of Impaired Glucose Tolerance

Materia Medica Holding·interventional·Posted Oct 30, 2018·Updated Feb 4, 2021

In Brief

A Phase 3 clinical trial evaluating Subetta and Placebo for Impaired Glucose Tolerance. Completed, enrolled 538 participants across 44 sites.

Detailed Summary

Purpose of the study: * to assess the efficacy of Subetta in the treatment of impaired glucose tolerance * to assess the safety of Subetta in the treatment of impaired glucose tolerance.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImpaired Glucose Tolerance
CountriesRussia
Collaborators--

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedOct 30, 2018
Enrollment StartOct 10, 2018
Primary CompletionMar 23, 2020
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 7.7 years ago

Interventions

Subettadrug

Oral administration.

Placebodrug

Oral administration.